Carac Articles
Merck KgaA unit and Isofol in deal for Modufolin in oncology
12 November 2009
Sanofi-Aventis and Regeneron discontinue one Ph III study of aflibercept
14 September 2009
UK’s NICE recommends Merck KGaA’s Erbitux cetuximab for the first-line treatment of metastatic colorectal cancer
26 August 2009
Pro-Pharma drug prevents mucositis
16 April 2009
Chemo post surgery cuts pancreatic cancer recurrence risk 30%
26 January 2009
Pro-Pharma's Davanat gets IND from FDA
8 September 2008
Sanofi terminates accord with Taiho
28 July 2008
Avastin + Herceptin HER2 study initiated
9 June 2008
Spear starts shipping generic Efudex
26 May 2008
Simcere acquires Zhong Ren Pharma
26 May 2008
Stock Commentary - New York week to May 19, 2008
26 May 2008
Curcumin/resveratrol boost FOLFOX efficacy
21 April 2008
Japan stock market week to March 10, 2008
17 March 2008
Strong early data on Davanat plus 5-FU in CRC
10 March 2008
Valeant sells Asia unit to Invida
10 March 2008
Roche's Xeloda gets EC OK for bowel cancer
14 February 2008
EC grants Xeloda broad approval for mCRC
11 February 2008
wt-KRAS as Erbitux efficacy biomarker
4 February 2008
CHMP recommends Taxotere SCCHN approval expansion
29 October 2007
14th annual ECCO conference hears exciting data on combination therapy with biologics
8 October 2007
X-ACT confirms Xeloda efficacy in bowel cancer
8 October 2007
Scottish cancer patients offered Xeloda
17 September 2007
"Compassionate-use" IND for Pro-Pharm's Davant
3 September 2007
Fast-track for Adventrx' ANX-510
3 September 2007
Valeant's 2nd-qtr 2007 income stays constant
13 August 2007
Pfizer initiates Ph III sunitinib trial in mCRC
9 July 2007
Stock Commentary - New York week to May 7, 2007
14 May 2007
Preclinical data suggests combo role for Proxinium
23 April 2007
Erbitux increases overall survival in SCCHN
16 April 2007
Xeloda gets nod for stomach cancer in Europe
5 March 2007
Strong data for Sanofi's Taxotere in node (+) breast cancer
22 December 2006
Patient dosing begins in Ph II Davanat trial
11 December 2006
Genentech's blockbuster Avastin gains new cancer indication; $2B sales predicted in 2007
23 October 2006
Valeant to commercialize Intendis products in UK
16 October 2006
Adventrx' CoFactor performs well in cancer model
25 September 2006
New study validates Roche's XELOX in colorectal cancer
7 August 2006
Sanofi and Taiho agree cancer-candidate deal
10 July 2006
Roche's Xeloda sees strong Ph III data
12 June 2006
Genentech submits Avastin sBLA to US FDA
5 June 2006
GPC starts Ph I study of satraplatin plus Xeloda
22 May 2006
Valeant 1st-qtr 2006 loss deepens to $6.4M
15 May 2006
Japan stock market week to April 17, 2006
24 April 2006
Genentech submits Avastin NSCLC sBLA
17 April 2006
Roche's Xeloda performs well in Ph III
17 April 2006
Spectrum acquires Targent's LFA assets
27 March 2006
Sanofi's xaliproden effective against PSN
20 February 2006
Roche suspends Avastin AVANT study
20 February 2006
Adventrx sees positive Ph II CoFactor cancer trial data
6 February 2006
Sanofi's Taxotere gets priority review for advanced gastric cancer
12 December 2005
DAVANAT/5-FU Phase II clinical trial initiated
5 September 2005
Adherex in $220M deal with GSK
25 July 2005
Roche's Xeloda "could replace 5-FU/LV"
11 July 2005
Adventrx' CoFactor sees good Ph II data
4 July 2005
Genentech's Avastin: good AE profile
27 June 2005
Regeneron/Sanofi-Aventis start VEGF trial
23 May 2005
Corgentech's cancer drug shows promise in vivo
27 April 2005
UK MHRA approves Adventrx' cancer trial
25 April 2005
Roche's Xeloda gains EU OK for colon cancer
11 April 2005
UPDATE: Roche's Avastin cleared in Europe
24 January 2005
Roche's Avastin cleared by EC
24 January 2005
Avastin cleared for cancer in Switzerland
10 January 2005
Sanofi-Aventis' Eloxatin gets new use
15 November 2004
BAY 43-9006 can be used with other drugs
8 November 2004
Roche's Avastin on track in EU
1 November 2004
Eloxatin cleared for expanded use in EU
27 September 2004
Aventis Taxotere gets OK for new use by FDA
23 August 2004
Genentech's Avastin linked to serious blood clots
23 August 2004
Sanofi to sell Aventis' Campto to Pfizer
5 July 2004
AP Pharma's 1st-qtr net loss jumps 42%
3 May 2004
Aphton reports positive PII G17DT data
16 February 2004
Sanofi files for extended Eloxatin use
26 January 2004
UPDATE: Eloxatin cleared by FDA as 1st line therapy
19 January 2004
Eloxatin cleared by FDA as 1st line therapy
19 January 2004
Aventis' Taxotere shows promise in early-stage breast cancer, filings expected 2004
15 December 2003
New wave of drugs offer hope in treatment of colon cancer
3 November 2003
OSI-7904L in Ph II for gastric cancer
3 November 2003
- Novo Nordisk's diabetes drug Victoza produced 8% weight loss in Ph III obesity trial
- Proposal to list Roche's Neulastim and Actemra in New Zealand
- Alchemia and Merck Serono collaborate on HA-Irinotecan with Erbitux
- Positive new data on Novartis' Galvus in elderly type 2 diabetes patients
- Johnson & Johnson expects 10 NDA filings by 2017, saying pharma sector poised for growth
